The short answer
No GLP-1 is FDA-approved specifically for PCOS, but they are widely prescribed off-label for the weight and insulin-resistance components, with growing trial evidence.
Zepbound specifically
Off-label for PCOS; on-label for obesity. Tirzepatide produces the largest average weight loss of the class.
BMI & eligibility
Most insurers approve a GLP-1 for a PCOS patient only through a weight-management (BMI ≥30, or ≥27 with comorbidity) or type-2-diabetes pathway, not for PCOS itself.
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
PCOS alone rarely gets coverage. The reliable path is qualifying through obesity (Wegovy/Zepbound) or, if blood sugar is elevated, prediabetes/diabetes documentation. Prior authorization usually needs BMI, a comorbidity, and documented lifestyle attempts.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for PCOS
Zepbound for other conditions
Sources
- GLP-1 receptor agonists in PCOS — systematic review — Journal of Clinical Endocrinology & Metabolism
- Drugs@FDA database — FDA
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.